NMPA approval for ELUNATE with TYVYT

Summary by AI BETAClose X

HUTCHMED and Innovent have announced NMPA approval for ELUNATE® (fruquintinib) in combination with TYVYT® (sintilimab injection) for locally advanced or metastatic renal cell carcinoma patients who have failed prior VEGFR-TKI therapy. This approval is based on the FRUSICA-2 study, which demonstrated a 63% reduced risk of disease progression or death, with a median progression-free survival of 22.2 months for the combination therapy compared to 6.9 months for axitinib/everolimus. The objective response rate was 60.5% for the combination versus 24.3% for the control arm. This marks the tenth approved indication for sintilimab and addresses a significant unmet need in China for advanced renal cell carcinoma treatment.

Disclaimer*

UK 100

Latest directors dealings